Update on Biologic Therapy in the Management of Axial Spondyloarthritis

Axial spondyloarthritis, which includes ankylosing spondylitis and psoriatic spondyloarthritis, is an important subtype of the spondyloarthritides. Tumor necrosis factor (TNF) antagonists are effective therapies for this partially heterogeneous group of rheumatic diseases in terms of signs, symptoms...

Full description

Saved in:
Bibliographic Details
Published in:Current rheumatology reports 2010-10, Vol.12 (5), p.325-331
Main Authors: Heldmann, Frank, Dybowski, Friedrich, Saracbasi-Zender, Ertan, Fendler, Claas, Braun, Jürgen
Format: Article
Language:English
Subjects:
Adalimumab
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antirheumatic Agents - therapeutic use
Biological Therapy
Etanercept
Humans
Immunoglobulin G - therapeutic use
Infliximab
Medicine
Medicine & Public Health
Receptors, Tumor Necrosis Factor - therapeutic use
Rheumatology
Spondylarthritis - therapy
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Axial spondyloarthritis, which includes ankylosing spondylitis and psoriatic spondyloarthritis, is an important subtype of the spondyloarthritides. Tumor necrosis factor (TNF) antagonists are effective therapies for this partially heterogeneous group of rheumatic diseases in terms of signs, symptoms, and functioning, but they do not seem to substantially inhibit radiographic progression, which is mainly new bone formation in ankylosing spondylitis. However, they clearly reduce inflammation, as shown by MRI. TNF blockers are also efficacious in the treatment of extraspinal features of spondyloarthritis. In addition, evidence indicates that anti-TNF therapy works well in early axial disease. Other biologics are currently being investigated, as alternatives are needed for patients who fail anti-TNF therapy.
ISSN:1523-3774
1534-6307
DOI:10.1007/s11926-010-0125-y